ClinicalTrials.gg

Program

SHR6508

A development code. Also written as “[14C] SHR6508 Injection”.

Its studies are mostly in Hyperparathyroidism, Secondary, led by Jiangsu HengRui Medicine.

Furthest: phase 2, since Dec 14, 20223 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Jiangsu HengRui Medicine30 open or runningphase 2since Dec 14, 2022Dec 14, 2022none ahead
  • Named in hansoh pharmaceutical group’s own pipeline as HS-10568 (Hengrui's SHR6508), phase 4, as of Aug 26, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 14, 2022First study: phase 2 study in Hyperparathyroidism, SecondaryFirst studyNCT05663411 · 75 enrolled · China
  2. Jan 9, 2024Phase 2 study in Hyperparathyroidism, SecondaryNCT06236295 · 303 enrolled · China
  3. Mar 10, 2025Phase 1 study in Hyperparathyroidism, SecondaryNCT06877247 · 5 enrolled · China

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06877247Hyperparathyroidism, Secondary · China1CompletedApr 4, 20255
NCT06236295Hyperparathyroidism, Secondary · China2CompletedNov 13, 2025303
NCT05663411Hyperparathyroidism, Secondary · China2UNKNOWNOct 31, 202375

How it is read

Names in the registry

  • “SHR6508”, 3 entries
  • “[14C] SHR6508 Injection”, 1 entry

Codes read as this program: SHR6508.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.